269 related articles for article (PubMed ID: 9270571)
21. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Kuno S
Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
[TBL] [Abstract][Full Text] [Related]
22. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.
Asin KE; Domino EF; Nikkel A; Shiosaki K
J Pharmacol Exp Ther; 1997 Apr; 281(1):454-9. PubMed ID: 9103530
[TBL] [Abstract][Full Text] [Related]
23. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
[TBL] [Abstract][Full Text] [Related]
24. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
[TBL] [Abstract][Full Text] [Related]
25. The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297.
Andringa G; Vermeulen RJ; Drukarch B; Renier WO; Stoof JC; Cools AR
Behav Pharmacol; 1999 Mar; 10(2):163-73. PubMed ID: 10780829
[TBL] [Abstract][Full Text] [Related]
26. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys.
Grondin R; Doan VD; Grégoire L; Bédard PJ
Neurology; 1999 Mar; 52(4):771-6. PubMed ID: 10078726
[TBL] [Abstract][Full Text] [Related]
27. Endogenous dopaminergic tone and dopamine agonist action.
Treseder SA; Smith LA; Jenner P
Mov Disord; 2000 Sep; 15(5):804-12. PubMed ID: 11009183
[TBL] [Abstract][Full Text] [Related]
28. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Andringa G; Lubbers L; Drukarch B; Stoof JC; Cools AR
Behav Pharmacol; 1999 Mar; 10(2):175-82. PubMed ID: 10780830
[TBL] [Abstract][Full Text] [Related]
29. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
Kebabian JW; Britton DR; DeNinno MP; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
Eur J Pharmacol; 1992 Dec; 229(2-3):203-9. PubMed ID: 1362704
[TBL] [Abstract][Full Text] [Related]
30. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
31. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Boraud T; Bezard E; Bioulac B; Gross CE
Brain; 2001 Mar; 124(Pt 3):546-57. PubMed ID: 11222455
[TBL] [Abstract][Full Text] [Related]
32. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
33. D
Mailman RB; Yang Y; Huang X
Eur J Pharmacol; 2021 Feb; 892():173760. PubMed ID: 33279520
[TBL] [Abstract][Full Text] [Related]
34. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Oh JD; Bibbiani F; Chase TN
Exp Neurol; 2002 Oct; 177(2):557-64. PubMed ID: 12429201
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
36. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
37. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
38. Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.
Gleason SD; Witkin JM
Behav Pharmacol; 2004 Feb; 15(1):85-9. PubMed ID: 15075630
[TBL] [Abstract][Full Text] [Related]
39. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
[TBL] [Abstract][Full Text] [Related]
40. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
